Issues related to plasma based therapies. H.R. 1476 / S. 694, Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act. Issues related to gene therapies. Issues related to value-based payments. Issues related to drug shortages. Monitored implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to plasma derived products and drug pricing. Issues related to pharmacy benefit management. Issues related to Most Favored Nation drug pricing.
2025 · 4th Quarter (Oct 1 - Dec 31)
CSL BEHRING LLC
Filed by THE NICKLES GROUP, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 4th Quarter - Report
- Posted
- Jan 20, 2026
- Income
- $50,000.00
- Expenses
- Not reported
- Registrant
- THE NICKLES GROUP, LLC
- Client
- CSL BEHRING LLC
- Filing UUID
- 3987e243-a795-4226-88f9-6b5b2bb21f1f
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Monitored issues related to medical supply chain and pharmacy benefit management. Monitored issues related to drug pricing. Issue regarding plasma-based therapies.
Monitored implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to foreign-based corporations, and corporate taxes. Issues related to the OECD Pillar II exemption for the U.S. H.R. 591, Defending American Jobs and Investment Act, and H.R. 2423, Unfair Tax Prevention Act, as they relate to multinational corporations.
Literal federal measure citations: H.R. 1, H.R. 591, H.R. 2423
Issues related to tariffs.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.